Authors : Thilagavathi M; Natarajan Kumaresan; Chandru Thirunavukkarasu; Rubina Singh

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/4d58rxyb

DOI : https://doi.org/10.38124/ijisrt/25jul517

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Background: Renal cell carcinoma (RCC) is the most common kidney cancer nearly 3% of all malignancies. Prominent advances in molecular biology and immunotherapy have revolutionized the understanding and treatment of RCC, resulting in favorable outcomes of patients. Objectives: This review focus on molecular mechanisms of RCC, diagnostic strategy advances, and emerging therapeutic strategies. Innovative therapies and areas of future research are highlighted with a view to augmenting personalized medicine. Materials and Methods: A systematic reviews was undertaken on medical article publications over the past 6 years. Mainly focused on renal cell carcinoma, molecular pathways, immune checkpoint inhibitors, and targeted therapies. Following the selection of articles, findings regarding RCC pathogenesis, diagnostics, and treatment advances were determined. Result: Recent research has also defined molecular changes, including Von Hippel Lindau (VHL) gene changes and hypoxia-inducible factors, that are responsible for RCC development. The advantages of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, as mono therapies or in combination with targeted therapy, have improved positive outcomes for advanced RCC. Conclusions: In RCC biology and immunotherapy have improved outcomes for kidney cancer. Continuous investigation into biomarkers and molecular targets is important for expanding personalized therapies, improving effect, and sustaining to enhance positive outcomes.

Keywords : Biomarkers, Hypoxia Inducible Factors, Immune Check Point Inhibitors, Immunotherapy, Renal Cell Carcinoma, Targeted Therapy.

References :

1. Capitanio, U., Montorsi, F. (2021). Renal cell carcinoma: Epidemiology, clinical presentation, diagnosis, and management. European Urology, 79(4), 501-515. https://doi.org/10.1016/j.eururo.2020.11.023
2. Linehan, W. M., et al. (2019). Molecular Classification of Renal Cell Carcinoma. Nature Reviews Urology, 16(4), 248-264.
3. Motzer, R. J., et al. (2023). Mechanisms of Resistance to Targeted Therapies in Renal Cell Carcinoma: Implications for New Treatment Strategies. Nature Reviews Urology, 20(2), 86-98. https://doi.org/10.1038/s41585-022-00612-1
4. Choueiri, T. K., et al. (2023). Emerging Therapeutic Targets and Future Directions in RCC. The Lancet Oncology , 24(4), 400-412. https://doi.org/10.1016/S1470-2045(23)00043-9
5. Rini, B. I., et al. (2022). Long-term Outcomes of Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal Cell Carcinoma: CheckMate 214. Journal of Clinical Oncology, 40(16), 1796-1806.
6. McDermott, D. F., et al. (2020). Biomarkers in Immunotherapy for Renal Cell Carcinoma: Current Perspectives and Future Directions. Nature Reviews Urology, 17(4), 227-238.
7. Gupta, M., et al. (2022). Emerging Biomarkers and Therapeutic Targets in Renal Cell Carcinoma. Cancer Treatment  Reviews, 103, 102278.
8. Albiges, L., et al. (2019). Molecular Subtypes of Clear Cell Renal Cell Carcinoma: Implications for Precision Medicine. Nature Reviews Urology, 16(9), 521-537.
9. Ding, H., et al. (2020). Genomic Characterization of Chromophobe Renal Cell Carcinoma. Nature Communications, 11, 598.
10. Srigley, J. R., et al. (2018). International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 42(9), 1233-1238.
11. Gorini, G., et al. (2018). Genetic and Epigenetic Alterations in Kidney Cancer. Cancer Biology & Therapy, 19(4), 359-370.
12. Hudes, G., et al. (2014). Temsirolimus, Interferon alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 356(22), 2271-2281.
13. Sato, T., et al. (2021). Molecular mechanisms and therapeutic targets in renal cell carcinoma: recent advances. Nature Reviews Urology, 18, 153-171.
14. Liu, Z., et al. (2023). Radiomics in Renal Cell Carcinoma: Applications, Challenges, and Future Directions. European Radiology, 33(4), 2492-2504.
15. McKay, R. R., et al. (2022). Integrating Genomics into Personalized Treatment of RCC: Progress and Challenges. Nature Reviews Urology, 19(3), 157-172. https://doi.org/10.1038/s41585-022-00588-7
16. Johnson, A., et al. (2022). Early Detection of Renal Cell Carcinoma Using Liquid Biopsies: Current Status and Future Perspectives. Cancer Research, 82(12), 2347-2355. https://doi.org/10.1158/0008-5472.CAN-22-0458